Ai Therapeutics, Inc.

Topotarget UK Limited

Curagen Corporation

Lam Therapeutics, Inc.

Quantum-si Incorporated

Amgen Fremont Inc.

Celldex Therapeutics Limited

A1 Therapeutics, Inc.

Al Therapeutics, Inc.

Orphal Therapeutics Inc.

Orphai Therapeutics Inc.

Celidex Therapeutics, Inc.

Henri Lichenstein

Jonathan Marc Rothberg

Sean Landrette

Thomas A Armer

Tian Xu

Lawrence S Melvin, Jr

Neil Beeharry

Paul Beckett

Chris Conrad

Sophia Gayle

James Ritchie

Michael Jeffers

William LaRochelle

Kamille Dumong Erichsen

Richard August Shimkets

Meijia Yang

John L Herrmann

Jonathan M Rothberg

Nicholas Edwards

Jane Plumb

Lawrence S Melvin

Peter R Young

Ferenc L Boldog

Catherine Burgess

Sudhirdas K Prayaga

Maxwell Sehested

Matt Dyer

Elma Fernandes

Xiaozhang Qian

Marylens Hernandez

Mike Jeffers

Orit Foord

Xiao-Chi Jia

Michael Torgov

Meina Liang

Peter S Mezes

Scott L Klakamp

Luca Rastelli

Muralidhara Padigaru

Umut Eser

Michael Meyer

Denise M Lepley

William Grosse

William F McDonald

Linda L Gorman

Carol E A Pena

John P Alsobrook, Ii

Daniel K Rieger

Kam Fai Tse

Juan Davagnino

Mei Zhong

Suresh G Shenoy

Andrei Chapoval

Cyrus Karkaria

Kamille Dumong Petersen

Traci Mansfield

Feng Xiao

Peter Ronald Young

Vincent A Pollack

Gulshan Ara

Michael E Jeffers

William J Larochelle

John Macdougall

William J LaRochelle

The present invention relates to methods and compositions for treating lymphangioleiomyomatosis in a human subject in need of such treatment. The methods comprise administering to the subject via inhalation an aerosol composition comprising rapamycin or a prodrug or derivative (including analog) thereof.

Rapamycin for the treatment of lymphangioleiomyomatosis

Methods and apparatus for predicting an association between input data in a first modality and data in a second modality using a statistical model trained to represent interactions between data having a plurality of modalities including the first modality and the second modality, the statistical model comprising a plurality of encoders and decoders, each of which is trained to process data for one of the plurality of modalities, and a joint-modality representation coupling the plurality of encoders and decoders. The method comprises selecting, based on the first modality and the second modality, an encoder/decoder pair or a pair of encoders, from among the plurality of encoders and decoders, and processing the input data with the joint-modality representation and the selected encoder/decoder pair or pair of encoders to predict the association between the input data and the data in the second modality.

Methods and apparatus for making biological predictions using a trained multi-modal statistical model

Provided are compositions and methods related to the use of apilimod in combination with glutamatergic agents for treating neurological diseases and disorders, and for the treatment of cancer.

Combination therapy with apilimod and glutamatergic agents

The present invention relates to methods and compositions for anti-aging therapy and for the treatment and prophylaxis of age-related diseases and disorders in a human subject in need of such therapy or treatment, the methods comprising the pulmonary administration to the subject, preferably via inhalation, of composition comprising rapamycin, or a prodrug or derivative thereof.

Inhalable rapamycin formulation for treating age-related conditions

The present invention relates to methods and compositions for the treatment and prophylaxis of pulmonary arterial hypertension (PAH) in a human subject in need of such treatment, the methods comprising the pulmonary administration to the subject, preferably via inhalation of a composition comprising rapamycin or a prodrug or derivative thereof.

Inhalable rapamycin formulation for the treatment of pulmonary hypertension

The present invention relates to methods for treating cancer with apilimod and related compositions and methods.

Apilimod compositions and methods for using same

The present disclosure relates to methods for treating renal cancer with apilimod and related compositions and methods.

Apilimod compositions and methods for using same in the treatment of renal cancer

The present invention pertains to a method for treating cancer, such as lung cancer, multiple myeloma, lymphoma, and epithelial ovarian cancer, comprising the administration to a patient in need thereof a first amount or dose of a histone deacetylase (HDAC) inhibitor, such as PXD-101, and a second amount or dose of another chemotherapeutic agent, such as dexamethasone or 5-fluorouracil, or an epidermal growth factor receptor (EGFR) inhibitor, such as Tarceva&#xda;, wherein the first and second amounts or doses together comprise a therapeutically effective amount.

Combination therapies using HDAC inhibitors

The disclosure also provides compositions and methods related to combination therapy with HSP90 inhibitors and BCL-2 pathway inhibitors for treating cancer. The disclosure also provides compositions and methods related to the use of 'low dose' HSP90 inhibitors in the treatment of cancer, alone and in combination with other therapeutic agents.

Methods for treating cancer using HSP90 inhibitors

The present invention relates to methods for treating melanoma with apilimod and related compositions and methods.

Apilimod for use in the treatment of melanoma

Growing community of inventors

Guilford, CT, United States of America

Henri Lichenstein